NO20090451L - Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol) - Google Patents
Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol)Info
- Publication number
- NO20090451L NO20090451L NO20090451A NO20090451A NO20090451L NO 20090451 L NO20090451 L NO 20090451L NO 20090451 A NO20090451 A NO 20090451A NO 20090451 A NO20090451 A NO 20090451A NO 20090451 L NO20090451 L NO 20090451L
- Authority
- NO
- Norway
- Prior art keywords
- pro
- igf
- variant
- pegylated
- glucole
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 title 1
- 239000005977 Ethylene Substances 0.000 title 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 7
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 7
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 238000011084 recovery Methods 0.000 abstract 2
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 abstract 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 abstract 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 abstract 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 abstract 1
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 abstract 1
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 abstract 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 abstract 1
- GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 abstract 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 abstract 1
- 108010087924 alanylproline Proteins 0.000 abstract 1
- 108010060035 arginylproline Proteins 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 abstract 1
- 108010077515 glycylproline Proteins 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000006320 pegylation Effects 0.000 abstract 1
- 108010029020 prolylglycine Proteins 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06018170 | 2006-08-31 | ||
| PCT/EP2007/007540 WO2008025528A1 (en) | 2006-08-31 | 2007-08-29 | Method for the production of conjugates of insulin-like growth factor-i and poly(ethylene glycol) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090451L true NO20090451L (no) | 2009-02-26 |
Family
ID=37667695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090451A NO20090451L (no) | 2006-08-31 | 2009-01-29 | Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol) |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US7625996B2 (ko) |
| EP (1) | EP2059261B1 (ko) |
| JP (1) | JP5184532B2 (ko) |
| KR (1) | KR101106931B1 (ko) |
| CN (1) | CN101511390B (ko) |
| AR (1) | AR062575A1 (ko) |
| AU (1) | AU2007291502B2 (ko) |
| BR (1) | BRPI0715943A2 (ko) |
| CA (1) | CA2662062C (ko) |
| CL (1) | CL2007002502A1 (ko) |
| CO (1) | CO6251278A2 (ko) |
| CR (1) | CR10591A (ko) |
| ES (1) | ES2397660T3 (ko) |
| IL (1) | IL196736A (ko) |
| MA (1) | MA30660B1 (ko) |
| MX (1) | MX2009002011A (ko) |
| NO (1) | NO20090451L (ko) |
| PE (1) | PE20080912A1 (ko) |
| RU (1) | RU2009106118A (ko) |
| TW (1) | TW200819468A (ko) |
| WO (1) | WO2008025528A1 (ko) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| WO2007093042A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| CN101484469B (zh) | 2006-08-31 | 2012-12-12 | 弗·哈夫曼-拉罗切有限公司 | 生产胰岛素样生长因子-ⅰ的方法 |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| ES2388827T3 (es) * | 2008-04-03 | 2012-10-19 | F. Hoffmann-La Roche Ag | Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares |
| EP2376099A4 (en) * | 2008-12-19 | 2012-04-25 | Univ Indiana Res & Tech Corp | YL-BASED INSULIN-LIKE GROWTH FACTORS EXPRESSING HIGH ACTIVITY AT THE INSULIN RECEPTOR |
| CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| JP5749744B2 (ja) * | 2010-02-11 | 2015-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｉｇｆ−ｉポリ（エチレングリコール）コンジュゲート |
| EP2582719B1 (en) | 2010-06-16 | 2016-08-10 | Indiana University Research and Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | アミド系インスリンプロドラッグ |
| GB201012784D0 (en) * | 2010-07-29 | 2010-09-15 | Ucb Pharma Sa | Method |
| BR112014015156A2 (pt) | 2011-12-20 | 2020-10-27 | Indiana University Research And Technology Corporation | análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira |
| US9493562B2 (en) | 2012-07-19 | 2016-11-15 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| CN108383902A (zh) | 2012-09-26 | 2018-08-10 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
| KR20150131213A (ko) | 2013-03-14 | 2015-11-24 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 인슐린-인크레틴 접합체들 |
| WO2014205617A1 (en) * | 2013-06-24 | 2014-12-31 | Shandong University | Lanthanide labeled peptide and use thereof |
| KR20160091888A (ko) | 2013-10-02 | 2016-08-03 | 노파르티스 아게 | 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체 |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| ES2947409T3 (es) | 2014-09-24 | 2023-08-08 | Univ Indiana Res & Tech Corp | Profármacos de insulina a base de amida lipídica |
| US10889625B2 (en) | 2016-02-23 | 2021-01-12 | The Regents Of The University Of Colorado, A Body Corporate | Peptide-based methods for treating neurological injury |
| EP3911668A1 (en) | 2019-01-18 | 2021-11-24 | The Regents of the University of Colorado, a body corporate | Amphipathic alpha-helical antimicrobial peptides treat infections by gram-negative pathogens |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3486216T2 (de) | 1983-04-25 | 1994-02-17 | Chiron Corp | Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren. |
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US6235488B1 (en) | 1988-09-29 | 2001-05-22 | Agilent Technologies, Inc. | Surface preparation for chemical-specific binding |
| DK0400472T3 (da) | 1989-05-27 | 1996-05-13 | Sumitomo Pharma | Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein |
| US6723699B1 (en) * | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
| US5158875A (en) | 1989-08-25 | 1992-10-27 | Amgen Inc. | Production of biologically active insulin-like growth factor i from high expression host cell systems |
| NZ236819A (en) * | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
| US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| WO1993002695A1 (en) | 1991-08-01 | 1993-02-18 | Genentech, Inc. | Igf-1 to improve the neural condition |
| US5861373A (en) | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| AU6048294A (en) | 1992-11-25 | 1994-06-22 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| CN1246891A (zh) | 1997-02-06 | 2000-03-08 | 诺沃挪第克公司 | 添加和/或除去了连接基团的多肽－聚合物偶联物 |
| US20030204864A1 (en) * | 2001-02-28 | 2003-10-30 | Henry Daniell | Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids |
| US6767892B1 (en) | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| US7067485B2 (en) | 1997-11-07 | 2006-06-27 | Chiron Corporation | IGF-I composition and its use |
| US6248546B1 (en) | 1998-03-09 | 2001-06-19 | Diagnostic Systems Laboratories, Inc. | Assay of IGFBP complex |
| AU3764199A (en) | 1998-04-29 | 1999-11-16 | Genentech Inc. | Spray dried formulations of igf-i |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| EP0972838B1 (en) | 1998-07-15 | 2004-09-15 | Roche Diagnostics GmbH | Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy |
| DK1141014T3 (da) | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulinlignende vækstfaktor (IGF) i mutantvariant |
| AU762047B2 (en) | 1999-01-06 | 2003-06-19 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
| DK1165119T3 (da) | 1999-04-08 | 2003-12-15 | Genentech Inc | Sammensætning baseret på modsat ladede polypeptider |
| US6596849B1 (en) | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
| US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
| CA2410974A1 (en) * | 2000-05-16 | 2002-11-15 | Dnavec Research Inc. | Polypeptides cleaving telomeric repeats |
| ES2301547T3 (es) * | 2000-05-16 | 2008-07-01 | Genentech, Inc. | Tratamiento de trastornos del cartilago. |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US20020082215A1 (en) | 2000-10-13 | 2002-06-27 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
| SI1355942T1 (sl) | 2000-12-07 | 2009-02-28 | Lilly Co Eli | Glp-1 fuzijski proteini |
| WO2002094853A2 (en) | 2001-05-21 | 2002-11-28 | Nektar Therapeutics Al, Corporation | Antibodies specific for poly(ethylene glycol) |
| MXPA05006945A (es) * | 2002-12-26 | 2005-12-14 | Mountain View Pharmaceuticals | Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor. |
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| PT2241575E (pt) | 2005-01-07 | 2015-09-16 | Regeneron Pharma | Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos |
| JP2009532027A (ja) * | 2006-03-28 | 2009-09-10 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ｉｇｆ−１ｒ抗体およびその使用 |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| ES2388827T3 (es) | 2008-04-03 | 2012-10-19 | F. Hoffmann-La Roche Ag | Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares |
-
2007
- 2007-08-28 CL CL200702502A patent/CL2007002502A1/es unknown
- 2007-08-29 WO PCT/EP2007/007540 patent/WO2008025528A1/en active Application Filing
- 2007-08-29 JP JP2009525971A patent/JP5184532B2/ja not_active Expired - Fee Related
- 2007-08-29 MX MX2009002011A patent/MX2009002011A/es active IP Right Grant
- 2007-08-29 EP EP07801961A patent/EP2059261B1/en active Active
- 2007-08-29 AU AU2007291502A patent/AU2007291502B2/en not_active Ceased
- 2007-08-29 AR ARP070103823A patent/AR062575A1/es not_active Application Discontinuation
- 2007-08-29 TW TW096132101A patent/TW200819468A/zh unknown
- 2007-08-29 CA CA2662062A patent/CA2662062C/en not_active Expired - Fee Related
- 2007-08-29 ES ES07801961T patent/ES2397660T3/es active Active
- 2007-08-29 PE PE2007001177A patent/PE20080912A1/es not_active Application Discontinuation
- 2007-08-29 RU RU2009106118/10A patent/RU2009106118A/ru not_active Application Discontinuation
- 2007-08-29 CN CN2007800319871A patent/CN101511390B/zh not_active Expired - Fee Related
- 2007-08-29 KR KR1020097003975A patent/KR101106931B1/ko not_active IP Right Cessation
- 2007-08-29 BR BRPI0715943-9A patent/BRPI0715943A2/pt not_active IP Right Cessation
- 2007-08-29 US US11/846,857 patent/US7625996B2/en not_active Expired - Fee Related
-
2009
- 2009-01-26 IL IL196736A patent/IL196736A/en active IP Right Grant
- 2009-01-29 NO NO20090451A patent/NO20090451L/no not_active Application Discontinuation
- 2009-01-29 CR CR10591A patent/CR10591A/es not_active Application Discontinuation
- 2009-01-30 CO CO09008773A patent/CO6251278A2/es not_active Application Discontinuation
- 2009-02-25 MA MA31660A patent/MA30660B1/fr unknown
- 2009-10-09 US US12/576,266 patent/US20100035817A1/en not_active Abandoned
-
2010
- 2010-04-27 US US12/767,829 patent/US20100210547A1/en not_active Abandoned
-
2012
- 2012-08-21 US US13/590,549 patent/US8476232B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008025528A1 (en) | 2008-03-06 |
| AR062575A1 (es) | 2008-11-19 |
| KR101106931B1 (ko) | 2012-01-25 |
| AU2007291502B2 (en) | 2012-05-31 |
| CN101511390A (zh) | 2009-08-19 |
| EP2059261A1 (en) | 2009-05-20 |
| US20100210547A1 (en) | 2010-08-19 |
| KR20090046875A (ko) | 2009-05-11 |
| CA2662062C (en) | 2015-06-23 |
| ES2397660T3 (es) | 2013-03-08 |
| CO6251278A2 (es) | 2011-02-21 |
| IL196736A (en) | 2013-10-31 |
| PE20080912A1 (es) | 2008-07-19 |
| US8476232B2 (en) | 2013-07-02 |
| US20100035817A1 (en) | 2010-02-11 |
| BRPI0715943A2 (pt) | 2013-07-30 |
| EP2059261B1 (en) | 2012-10-24 |
| CL2007002502A1 (es) | 2008-05-30 |
| JP2010501192A (ja) | 2010-01-21 |
| IL196736A0 (en) | 2009-11-18 |
| CA2662062A1 (en) | 2008-03-06 |
| US20080119409A1 (en) | 2008-05-22 |
| CN101511390B (zh) | 2013-04-24 |
| TW200819468A (en) | 2008-05-01 |
| MX2009002011A (es) | 2009-03-05 |
| JP5184532B2 (ja) | 2013-04-17 |
| MA30660B1 (fr) | 2009-08-03 |
| AU2007291502A1 (en) | 2008-03-06 |
| US20130065831A1 (en) | 2013-03-14 |
| RU2009106118A (ru) | 2010-10-10 |
| CR10591A (es) | 2009-04-03 |
| US7625996B2 (en) | 2009-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090451L (no) | Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol) | |
| US11142550B2 (en) | Split inteins with exceptional splicing activity | |
| WO2008025527A8 (en) | Method for the production of insulin-like growth factor-i | |
| ES2633894T3 (es) | Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas | |
| Li et al. | Cloning, expression, isotope labeling, and purification of human antimicrobial peptide LL-37 in Escherichia coli for NMR studies | |
| DK1874932T3 (da) | Produktion af rekombinante proteiner ved autoproteolytisk spaltning af et fusionsprotein | |
| EP1392717A4 (en) | FAST CLEAVABLE SUMOFUSION PROTEIN EXPRESSION SYSTEM FOR HEAVY-TO-EXPRESS PROTEINS | |
| Lin et al. | Aggregating tags for column‐free protein purification | |
| Yang et al. | Expression and purification of the antimicrobial peptide cecropin AD by fusion with cationic elastin-like polypeptides | |
| DE60231055D1 (de) | Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie | |
| Liew et al. | Preparation of recombinant thioredoxin fused N-terminal proCNP: analysis of enterokinase cleavage products reveals new enterokinase cleavage sites | |
| WO2007095320A4 (en) | Hpv antigens, vaccine compositions, and related methods | |
| EP2115156A2 (en) | Multimeric elp fusion constructs | |
| Li | Production of human antimicrobial peptide LL-37 in Escherichia coli using a thioredoxin–SUMO dual fusion system | |
| DK1905839T3 (da) | Fremgangsmåde til fermentativ fremstilling af proteiner | |
| WO2007125371A3 (en) | Process for making oligopeptides | |
| KR20140004219A (ko) | 대장균에서 이형 단백질 생산을 위한 새로운 발현 및 분비 벡터 시스템 | |
| Yuan et al. | Expression, purification, and characterization of a biologically active bovine enterokinase catalytic subunit in Escherichia coli | |
| KR100961528B1 (ko) | 대장균에서 활성형 인간 상피세포 성장인자의 대량제조방법 | |
| WO2016161983A1 (zh) | 一种融合载体蛋白及其在促进目的蛋白或多肽表达中的应用 | |
| US20160122793A1 (en) | Fusion Protease | |
| CA2324513A1 (en) | Chimeric protein containing an intramolecular chaperone-like sequence and its application to insulin production | |
| GB201102700D0 (en) | Protein secretion | |
| Wang et al. | A novel strategy for the preparation of codon-optimized truncated Ulp1 and its simplified application to cleavage the SUMO fusion protein | |
| CN108165570A (zh) | 一种利用蛋白质酶切位点形成包涵体并制备小肽的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |